Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,963 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,963 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Open enrollment, early-phase tilt
HIV Infections has 615 registered US clinical trials, 56 of them open to new participants right now, about 9% of the total.
- 56
- recruiting participants now
- 9%
- of trials open to enrollment
- 92
- in Phase 3-4 (later-stage)
- 195
- top sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Corpus placement: #7 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 6 of 13
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000691
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
Boehringer Ingelheim
NCT00552240
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
Bavarian Nordic
NCT00189904
Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy
Massachusetts General Hospital
NCT00338767
Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00028314
PrEP2Prevent An Online PrEP Navigation and Activation Intervention
Children's Hospital Los Angeles
NCT05281393
Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru
Florida International University
NCT05873855
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT04636437
The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000848
Pain and Sensory Changes Assessment in HIV+ Patients
University of Medicine and Dentistry of New Jersey
NCT00422695
A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000653
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
ViiV Healthcare
NCT04484337
Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults
ViiV Healthcare
NCT03945981
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00339040
Antiviral Therapy and HIV in the Female Genital Tract
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00067106
Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00992017
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000779
HIV and Cardiovascular Risk
Massachusetts General Hospital
NCT00465426
A Study of HIV Levels During Pregnancy and After Childbirth
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00041964
A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000837
A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults
ViiV Healthcare
NCT07066722
Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT03819114
Evaluation of Patients Who Have Not Had Success With Zidovudine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001025
Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3
G D Searle
NCT00001993
Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001097
Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000810
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
Johns Hopkins University
NCT00130819
Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00028132
Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00115960
Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma
National Institutes of Health Clinical Center (CC)
NCT00226304
The Effects of Prednisone on HIV Levels and the Immune System
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000921
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00046033
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
University of California, San Francisco
NCT03207945
Anti-HIV Medications for People Recently Infected With HIV
Johns Hopkins Bloomberg School of Public Health
NCT00106171
Preventing HIV/Aids in Drug Abusing Youth
Oregon Research Institute
NCT00680719
Directly Administered HIV Therapy in Methadone Clinics
Johns Hopkins University
NCT00279110
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
Gilead Sciences
NCT01363011
The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001057
Effectiveness of a Cell Phone-Based Program for Abstinence and HIV Risk Prevention
University of Colorado, Denver
NCT00601237
Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
Solvay Pharmaceuticals
NCT00642499
Internet-based HIV/STI Prevention for Young MSM Receiving HIV Testing
University of Illinois at Chicago
NCT00968188
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00257127
Evaluation of the DPP HIV 1/2 Test and the HIV 1/2 Stat Pak Test Using Oral Fluid
Chembio Diagnostic Systems
NCT00636220
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
Gilead Sciences
NCT00224445
Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00006291
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
ViiV Healthcare
NCT03016533
The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
Gilead Sciences
NCT00002379
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000764
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02741323
A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001015
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for HIV Infections right now
56 recruiting of 615 indexed (9% open).
Phase mix: 92 late (III/IV) vs 266 early (I/II) (early-phase heavy).
Top sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (195 trials), 9 others listed. 50 shown below, recruiting first. #7 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for HIV Infections?
PlainTrial tracks 615 US clinical trials for HIV Infections, of which 56 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for HIV Infections?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.